SlovakNews

Slovakia

Slovak parliament approves medicine reimbursement reform, sets phased rollout

The Health Ministry-backed amendment overhauls reimbursement for medicines, medical devices and dietetic foods, with most rules starting in the coming months and exception-medicine changes from January 2027 – winning patient-group praise but opposition warnings on cost.

Live Version: 2Sources: 9Perspectives: 1Updated:
Foto: Pravda · source

What's new

  • Parliament approved the medicine-policy reform on Oct 6, after the government had approved the draft on May 6.
  • Most provisions take effect in the coming months; rules for exception-medicine reimbursement start January 2027.
  • A new budget ceiling for medicine-policy spending will be introduced.
  • Patient and rare-disease advocacy groups welcomed the law after 18 months of negotiation.
  • Opposition lawmakers warned the reform could substantially increase healthcare costs.

Slovak lawmakers approved a Health Ministry-backed reform of medicine reimbursement policy on Tuesday, Oct 6, changing rules governing medicines, medical devices and dietetic foods. Most provisions are due to take effect in the coming months, with changes to exception-medicine reimbursement starting January 2027, while patient groups welcomed the law and opposition lawmakers warned of rising costs.3462

Exceptional reimbursement

The legislation revises the process used when patients seek exceptional reimbursement for medicines that are not ordinarily covered by public health insurance. In selected cases, the medicine must have no substitute among reimbursed treatments, and effective covered options must already have been exhausted. The assessment of treatment effect can include improvement or stabilisation of a patient’s condition, or slower disease progression, provided safety and tolerance are acceptable.3

Healthcare providers will submit exceptional-reimbursement applications using insurers’ forms. When an application is incomplete, an insurer is to request additional information within 15 working days, after which the provider will have 20 working days to supply it. Unless the provider asks for a shorter period, approval for exceptional reimbursement is to be granted for at least six months.3

The Health Ministry expects the rules to improve access to modern treatment and make insurers’ decisions more predictable. It said the amendment responds to medicine availability, the sustainability of public health-insurance resources and difficulties encountered when applying the existing law.34

The amendment also moves the rules governing exceptional-medicine reimbursement out of insurers' internal policies and into law, intended to give patients a firmer legal claim to such treatment rather than leaving decisions solely to insurers' discretion. It also establishes a budget ceiling for medicine-policy spending, and patients already receiving treatment will be able to continue it despite subsequent market or price changes.3

Entry of new treatments

Selected new medicines will be eligible to enter the standard reimbursement system under specified conditions without initially meeting the usual cost-effectiveness requirement. The amendment also establishes particular entry conditions for medicines treating rare diseases. According to the explanatory report cited by Noviny.sk, a comparable mechanism had previously been used only three times.3

Price agreements are to include reimbursement limits covering the first three years after a medicine enters the system. If a medicine is subsequently removed from reimbursement, its registration holder will be required to finance continued treatment for patients already receiving it, for no longer than the period established by law.3

The changes also cover dietetic foods and medical devices. Noviny.sk reported that 10 dietetic products classed as basic foods had been removed from the system since 2022 under the previous arrangements.3

Controls and legal alignment

The reform includes measures intended to curb illegal re-export of medicines and strengthen oversight of medicine trading and prescription forgery. It also contains legislative and technical changes designed to clarify basic definitions and increase legal certainty across human and veterinary pharmacy, transfusion services and medicine-distribution chains.14

The amendment is also intended to align Slovak legislation with European Union law and international standards. The ministry has presented the broader package as balancing improved medicine availability with the sustainability of the public health-insurance system.34

Timing and reactions

The government approved the draft reform on May 6, citing seven key changes intended to improve medicine availability and curb illegal re-export, before parliament passed it on Oct 6. Most provisions are expected to take effect in the coming months, while changes to exception-medicine reimbursement are due to apply from January 2027.136

Patient and rare-disease groups, represented by the Platform of helping organisations, welcomed the law's approval, saying more than a year and a half of negotiation involving patients, doctors, insurers, the public ombudsman, the Health Care Surveillance Authority and the pharmaceutical sector had shown that compromise was possible despite differing interests. They cautioned, however, that the law's success would depend on timely regulations, clear procedures and sufficient financing, and that real, predictable access to treatment – not the law's existence alone – was what mattered for rare-disease patients.2

Opposition lawmakers offered a more mixed assessment. SaS healthcare expert Tomáš Szalay and PS MP Oskar Dvořák said the reform would improve access to medicines but warned it could prove very costly and lacked clear prioritization or an overall medicine-policy strategy. Separate reporting on the government's May approval cited analysts projecting annual costs could reach roughly €190 million by 2029, and cited concerns from Conservatives-Christian Union representative Helena Hlubocká that Slovakia's funding lagged the Czech Republic's. Ombudsman Róbert Dobrovodský had long criticised the previous exception-medicine system.35

Why it matters

The reform affects how patients in Slovakia may obtain innovative and exceptionally reimbursed treatments, as well as how insurers and pharmaceutical companies manage access and costs. Its phased rollout and new budget ceiling have sparked debate between patient advocates, who welcomed the law after lengthy negotiations, and opposition lawmakers warning of rising costs to the public health-insurance system.235

Related stories

Version history

  1. version 2 · Added reporting on the reform's phased effective dates (most rules soon, exception-medicine rules from January 2027), its new budget ceiling, patient-group praise after 18 months of talks, and opposition warnings about rising healthcare costs.
  2. version 1 ·